What We're Reading: Page 76
Industry reads hand-picked by our editors
Sep 15, 2023
-
Reuters
Bayer’s new CEO plans to cut management jobs in prelude to overhaul
-
Bloomberg
Covid Vaccine Maker Moderna Faces Tougher Competition
-
Fierce Biotech
FDA resource constraints delay decision on Iovance cell therapy
-
AP News
Psychedelic drug MDMA eases PTSD symptoms in a study that paves the way for possible US approval
Sep 14, 2023
-
Nature
‘A Pandora’s box’: map of protein-structure families delights scientists
-
The New York Times
The Stock Market Hopes Arm’s IPO Is a Hit
-
Fierce Biotech
AbbVie drops Harpoon’s BCMA drug, ending dream of $200M payday
-
MIT Technology Review
She was a semi-pro Go player but learned that biology is even harder
Sep 13, 2023
-
AP News
Popular nasal decongestant doesn’t actually relieve congestion, FDA advisers say
-
Axios
Biden admin previews defense of drug price negotiations
-
Fierce Biotech
Roche places ‘stronger gates’ on phase 3 pipeline to limit failures
-
The Times
AstraZeneca’s drugs chief Sir Mene Pangalos cures his work-life balance
Sep 12, 2023
-
Science
Her work paved the way for blockbuster obesity drugs. Now, she’s fighting for recognition
-
Reuters
AstraZeneca seeks to calm CEO speculation after shares drop
-
C&EN
Long COVID: The hunt for causes and cures
-
AP News
Patients need doctors who look like them. Can medicine diversify without affirmative action?
Sep 11, 2023
Sep 08, 2023
-
Fierce Pharma
Patent cliffs and divestitures point to an uptick in M&A
-
Nature Medicine
Pioneering the path to NASH biomarker approval
-
Healthcare Dive
‘Revolving door’ between HHS and industry could influence regulation, study says
Sep 07, 2023
-
The Atlantic
We Have No Drugs to Treat the Deadliest Eating Disorder
-
FirstWord Pharma
J&J scraps late-stage pulmonary hypertension study of macitentan
-
Gizmodo
Counterfeit Pills Are Becoming Deadlier in America
-
The Wall Street Journal
Health-Insurance Costs Are Taking Biggest Jumps in Years
Previous
